Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Jazz Pharmaceuticals plc shares valued at $55,000 were sold by COZADD BRUCE C on Jun 03 ’25. At $110.00 per share, COZADD BRUCE C sold 500 shares. The insider’s holdings dropped to 437,973 shares worth approximately $47.94 million following the completion of this transaction.
Also, COZADD BRUCE C sold 500 shares, netting a total of over 53,950 in proceeds. Following the sale of shares at $107.90 each, the insider now holds 438,473 shares.
Before that, COZADD BRUCE C had added 1,000 shares to its account. In a trade valued at $108,950, the Officer bought Jazz Pharmaceuticals plc shares for $108.95 each.
As published in a research note from UBS on March 07, 2025, Jazz Pharmaceuticals plc [JAZZ] has been rated up from a Neutral to a Buy and the price target has been revised to $179 from $145. Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in late February. As of February 13, 2025, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for JAZZ. Earlier on December 12, 2024, Morgan Stanley upgraded its rating. Their new recommendation was “an Overweight” for JAZZ stock which previously was a “an Equal-weight”.
Analyzing JAZZ Stock Performance
During the last five days, there has been a surge of approximately 2.28%. Over the course of the year, Jazz Pharmaceuticals plc shares have dropped approximately -11.12%. Shares of the company reached a 52-week high of $148.06 on 02/26/25 and a 52-week low of $95.49 on 04/09/25.
Support And Resistance Levels for Jazz Pharmaceuticals plc (JAZZ)
According to the 24-hour chart, there is a support level at 108.48, which, if violated, would cause prices to drop to 107.52. In the upper region, resistance lies at 111.35. The next price resistance is at 113.26. RSI (Relative Strength Index) is 50.47 on the 14-day chart, showing neutral technical sentiment.
